Archive · 24 Jul 2025
ICMR's New Malaria Vaccine Gives Hope for the Future
Scientists have developed a new vaccine called AdFalciVax to fight malaria, a disease spread by mosquitoes.
This vaccine works by targeting the malaria parasite in two ways: stopping it from infecting people and preventing it from spreading further.
It's shown great promise in initial tests on mice, with over 90% success.
The vaccine may also offer longer-lasting protection than other available vaccines.
Researchers aim to partner with a company to conduct trials on humans and manufacture the vaccine.
While the vaccine is promising, more testing is needed before it can be used widely.
The ICMR will retain control of the vaccine's intellectual property.
ICMR announced a new malaria vaccine candidate called AdFalciVax, for commercial development.
AdFalciVax targets two parts of the Plasmodium falciparum parasite, the most common malaria source.
AdFalciVax uses CSP and Pro6C proteins to prevent infection and stop the spread of disease.
The vaccine showed over 90% protection in mice and may have a longer-lasting immune response.
ICMR seeks a private partner for human trials, production, and will retain intellectual property rights.
- Who
- The Indian Council of Medical Research (ICMR).
- What
- ICMR announced a promising new malaria vaccine candidate, AdFalciVax.
- When
- Recently announced, with further development planned.
- Where
- India, with global implications for malaria control.
- Why
- To combat malaria, a disease that claims approximately 400,000 lives annually.
ICMR
Private Companies
IP Ownership and Commercialization
ICMR
ICMR will partner with a private company for vaccine development, retaining intellectual property rights.
Private Companies
Private company gains rights to develop and profit from a vaccine created with ICMR technology.
- Vaccine Name
- AdFalciVax
- Target Parasite
- Plasmodium falciparum
- Primary Function
- Prevent infection & transmission
- Protection in Mice
- Over 90%
- Intellectual Property
- ICMR retains ownership
- Adjuvant
- Alum